Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate long-term safety and patient acceptability
of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol
Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT
Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.